Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso - News 69

Breaking

Post Top Ad

Post Top Ad

Wednesday, March 20, 2019

Sage Therapeutics stock rises after FDA approves first postpartum depression drug Zulresso

Zulresso is an IV injection used to treat the sometimes life-threatening condition of postpartum depression, which is a major depressive episode that occurs following or leading up to childbirth.

No comments:

Post a Comment

Post Top Ad